Omeros (NASDAQ:OMER) Now Covered by Analysts at D. Boral Capital

Analysts at D. Boral Capital started coverage on shares of Omeros (NASDAQ:OMER - Get Free Report) in a research note issued on Monday, Marketbeat Ratings reports. The brokerage set a "buy" rating and a $36.00 price target on the biopharmaceutical company's stock. D. Boral Capital's target price would indicate a potential upside of 256.08% from the company's previous close.

Several other analysts have also recently commented on OMER. StockNews.com upgraded shares of Omeros from a "sell" rating to a "hold" rating in a report on Wednesday, November 20th. Rodman & Renshaw assumed coverage on shares of Omeros in a report on Thursday, November 14th. They set a "buy" rating and a $9.00 price target on the stock. Cantor Fitzgerald reaffirmed a "neutral" rating on shares of Omeros in a research note on Thursday, November 14th. Needham & Company LLC reissued a "hold" rating on shares of Omeros in a research report on Thursday. Finally, RODMAN&RENSHAW raised Omeros to a "strong-buy" rating in a research report on Thursday, November 14th. Three equities research analysts have rated the stock with a hold rating, two have issued a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, the stock has an average rating of "Moderate Buy" and a consensus target price of $22.50.

Omeros Trading Down 1.9 %

NASDAQ OMER traded down $0.20 during trading on Monday, reaching $10.11. 950,691 shares of the company's stock were exchanged, compared to its average volume of 552,035. Omeros has a fifty-two week low of $2.61 and a fifty-two week high of $13.60. The company's fifty day simple moving average is $7.09 and its 200-day simple moving average is $5.20. The firm has a market capitalization of $585.87 million, a PE ratio of -4.38 and a beta of 1.97.

Hedge Funds Weigh In On Omeros

Several institutional investors have recently bought and sold shares of OMER. MML Investors Services LLC boosted its stake in shares of Omeros by 19.2% during the 3rd quarter. MML Investors Services LLC now owns 18,600 shares of the biopharmaceutical company's stock worth $74,000 after acquiring an additional 3,000 shares in the last quarter. State Street Corp boosted its position in Omeros by 0.3% during the third quarter. State Street Corp now owns 1,226,053 shares of the biopharmaceutical company's stock worth $4,867,000 after purchasing an additional 3,839 shares during the period. HighTower Advisors LLC grew its holdings in Omeros by 7.2% during the third quarter. HighTower Advisors LLC now owns 59,339 shares of the biopharmaceutical company's stock valued at $235,000 after purchasing an additional 4,000 shares during the last quarter. Rhumbline Advisers raised its position in shares of Omeros by 6.1% in the second quarter. Rhumbline Advisers now owns 111,778 shares of the biopharmaceutical company's stock valued at $454,000 after purchasing an additional 6,435 shares during the period. Finally, Geode Capital Management LLC raised its position in shares of Omeros by 0.5% in the third quarter. Geode Capital Management LLC now owns 1,339,251 shares of the biopharmaceutical company's stock valued at $5,318,000 after purchasing an additional 6,839 shares during the period. 48.79% of the stock is currently owned by institutional investors.

About Omeros

Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases, including complement-mediated diseases, cancers, and addictive and compulsive disorders. The company's products under development include Narsoplimab (OMS721/MASP-2) that has completed pivotal trial for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); that is in Phase III clinical trial for the treatment of immunoglobulin A nephropathy (IgAN); and Phase II clinical trial to treat COVID-19.